The evolution of prosthetic heart valves has improved durability, thrombogenicity, and hemodynamics, enhancing clinical outcomes and patient quality of life.
Provides a comprehensive historical and contemporary overview of the evolution of surgical and endovascular prosthetic heart valves.
Absolute Event Rate: 0% vs 0%
Since Dr. Charles Hufnagel introduced the first ball-in-cage valve prosthesis in 1952 to treat a patient with aortic regurgitation, the field of valvular heart disease has undergone remarkable evolution in both prosthetic valve development and patient management. Over the past 73 years, a wide range of valvular prostheses have been developed, each offering distinct advantages in terms of durability, thrombogenicity, and hemodynamics. This review aims to provide a detailed discussion of commonly known and used valvular heart prostheses, along with a review of newer endovascular prostheses. As ongoing research and innovation continue to shape the field, we can expect further improvements in hemodynamics, clinical outcomes, cost, ease of operation, and patient quality of life.
Tabassum et al. (Fri,) reported a other. The evolution of prosthetic heart valves has improved durability, thrombogenicity, and hemodynamics, enhancing clinical outcomes and patient quality of life.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: